[ad_1]
Contrast with Korea, which took a stand on bioethics
Japan is pacing in the field of regenerative medicine. Approved a clinical trial of Parkinson's disease using inducible pluripotent stem cells (iPS cells). It is the third treatment after macular degeneration and treatment of heart disease.
The Japanese government granted permission to request clinical trials for the treatment of Parkinson's disease under development by Professor Takahashi Junichiro of Kyoto University, and the Japanese press, including the Yomiuri Shimbun, according to the report. IPS cells are not embryos or oocytes, but multipotent somatic cells, such as stem cells, that allow them to differentiate in all cells. This is the first time in the world that a clinical trial using iPS cells to treat Parkinson's disease
The clinical content is the creation of cerebral nerve cells from iPS cells and their implantation into the brain of Parkinson's patients. Researchers plan to start clinical trials sooner or later.
Human nerve cells in the brain produce dopamine, an information transmitter that regulates movement. Parkinson's disease is a disease caused by the reduction of these nerve cells. Muscular rigidity, body tremors, and slow movement are typical symptoms of Parkinson's disease. Alzheimer's disease, stroke and other diseases are one of the three major geriatric diseases, about 160,000 in Japan and about 100,000 in Korea.
There have been two clinical trials in Japan that have implanted cells made with iPS cells in patients. 2014 macular degeneration treatment, approved last year for the treatment of severe heart disease treatment. Last month, the Japanese government approved a clinical research plan to implant muscle cells composed of iPS cells in the heart of patients with severe heart failure.
South Korea points out that she is late in the field of regenerative medicine. Hwang Woo-suk, and so on, came from the fact that the power of stem cell research has dropped and regulations such as embryonic stem cells have been blocked. Research on SPI cell research is also slow. There are about 40 patents in Japan and 10 patents in Korea.
By Yang Byung Hun reporter [email protected]
prohibiting Han Kyung dot com, prohibition of reprinting and redistribution
Source link
